ETIOPATHOGENICAL ASPECTS OF NONSTEROIDAL ANTI- INFLAMMATORY DRUGS IN ELDERLY Mihaela Bursova¹, Gabriela Lilios², Maria Suta³, Gh.
|
|
- Raymond Jenkins
- 5 years ago
- Views:
Transcription
1 ETIOPATHOGENICAL ASPECTS OF NONSTEROIDAL ANTI- INFLAMMATORY DRUGS IN ELDERLY Mihaela Bursova¹, Gabriela Lilios², Maria Suta³, Gh. Taralunga² 1.CLINICAL EMERGENCY COUNTY HOSPITAL CONSTANŢA, GERIATRICS DEPARTAMENT 2. FACULTY OF PHARMACY, OVIDIUS UNIVERSITY, CONSTANŢA 3. FACULTY OF MEDECINE, OVIDIUS UNIVERSITY, CONSTANŢA Summary Nonsteroidal anti-inflammatory (NSAIDs) induced gastritis still represent one of the most frequent medical problems, especially in elderly patients, due to its increased prevalence and also due to its increased morbidity and mortality. Although gastritis are often associated with NSAIDs, evidences about predicting factors of their development in patients taking NSAIDs are poor. In addition, the ulcerogenic potentials of the newer NSAIDs are still compared with those of more established preparations (conventional NSAIDs). The aim of this study was to identify the relationship between the type of NSAIDs and their potential to produce gastric complications and also between NSAIDs and HP infection. Altogether 172 long term NSAIDs users, aged 65 years or over, were studied. The presence of abdominal complaints, previous history of ulcers, endoscopic and histological features and Helicobacter Pylori status were all assessed. NSAIDs were classified into conventional drugs(group 1) and newer agents(group 2). Group 1 included indomethacin, diclofenac,ketoprofen, piroxicam. Group 2 included meloxicam, celecoxib, etoricoxib. As in other recent clinical trials, at risk patients in our study ( 65 of age, concurrently taking low-dose aspirin ) taking conventional NSAIDs had a higher incidence of gastric complications (bleedings) than those taking selective COX-2 inhibitors. The HP infection status was very important to asses, but it was possible only for 120 patients. To these patients the result were 68 HP positive and 52 HP negative. HP infection and NSAIDs are independent risk factors for chronic gastritis and no difference in terms of gastric complications was observed between these two groups. (NSAIDs users HP positive and NSAIDs users HP negative) Key words: gastritis, NSAIDs, elderly, endoscopy, helicobacter pylori. Introduction NSAIDs are extensively used pharmaceuticals agents they are well known and widely used for their antiinflammatory, analgetic and antipyretic properties. Incidence of gastrointestinal side effects of NSAIDs is relatively high and common, being an important cause of death (over 2000 person in Great Britain and possibly in USA, especially in elderly) Over the years several attemps have been made to predict the complications of gastritis (ulcerations, bleedings, perforations). Despite the increase frequency of gastritis in patients taking 202 abursova@yahoo.com nonsteroidal anti-inflammatory drugs (NSAIDs) very little is known about the risk factors for their development. Some aspect are not clear because: 1. NSAIDs-induced gastritis can be completely asymptomatic. 2. Various NSAIDs may differ or not in their potential to produce gastritis. 3. The precise contribution of HP infection to NSAIDs-related gastritis is not fully defined. 4. The specificity of some serological tests for HP may be low in chronic NSAIDs users, especially in elderly (Taha, 1994).
2 These study aimed therefore, to assess if the type of NSAIDs or the H. Pylori status are important in order to influence the clinical and endoscopical aspects of NSAIDs gastritis in elderly. Gastroduodenal mucosa possesses an array of defensive mechanisms and nonsteroidal anti-inflammatory drugs (NSAIDs) have a deleterious effect on most of them. NSAIDs appear to cause gastro-duodenal damage, by two main mechanisms: a physiochemical disruption of the gastric mucosal barrier and a systemic inhibition of gastric mucosal protection, through inhibition of cyclo-oxygenase activity of gastro-intestinal (GI) mucosa. A reduced synthesis and secretion of mucus and bicarbonate, an impairment of mucosal blood flow and an increase of acid secretion represent the main consequences of NSAID-induced prostaglandin (PG) deficiency. Additional mechanisms which may add to the damage have been demonstrated. These include uncoupling of oxidative phosphorylation, reduced mucosal cell proliferation and DNA synthesis as well as neutrophil activation. After administration of NSAIDs, neutrophil adherence to the vascular endothelium occurs, with consequent reduced mucosal perfusion and release of tissue-damaging mediators (Scarpignato, 1995). Material and methods This study was performed on 172 patients (136 F /36 M, aged 65 years) admitted in Gastroenterology Department of Constanta Emergency Clinical Hospital between Octomber 2006 Octomber In this period 306 elderly patients with gastritis were identified, but only those 172 with NSAIDs induced gastritis were further studied (56.2%). All the pacients were considered long- term users of NSAIDs (they had taken drugs at least 4 weeks in the last 3 months). Patients were excluded if they were <65 years old, if they had had gastric surgery or if they had taken anti-ulcer drugs or antibiotics within a week of endoscopy. All of them 203 underwent upper digestive endoscopy for various gastric complaints. Biopsies were taken from the antrum for H. Pylori testing (by histology -two specimens and also by a Rapide Urease Test- RUT) and from lesions if present. The RUT, in which presence of bacterial urease in the biopsy sample causes a color change on a special medium, is the diagnostic method of choice on tissue samples. Histologic staining of biopsy samples was done for those pacients with negative RUT results, but suspicious clinical findings. Biopsy specimens were stained with hematoxyline-eosine and with modified Giemsa for H. Pylori and RUT was performed with CLO test. RUT and histologic staining each have a sensitivity and specificity of 90%. The endoscopic examination was usefull also to describe the lesions NSAIDsinduced (size, number, site and type: edema, eritema, erosions, ulcerations, hemorrhaging lesions). Blood was taken to measure the haemoglobin concentration, erythrocyte sedimentation rate (ESR) and C reactive protein (CRP). Gastritis was classified according to the Sydney Sistem. The following characteristics were assessed : 1. Upper abdominal symptoms; 2. Presence of comorbidities (cardio vascular diseases, diabetes, CRF, cerebral strokes, COPD, osteoporosis, malignances) 3. Previous history of ulcers ; 4. Helicobacter Pylori status. NSAIDs were divided into two groups: group 1 (conventional or older agents) including indomethacin, dyclofenac, ketoprofen, piroxicam and group 2 (newer agents ) including lornoxicam, meloxicam, celecoxib, etoricoxib. The potential of most of the newer preparations to produce gastritis had been assessed previously in short term trials only.
3 In a recent clinical trial, at-risk patients (>65 years of age and/or a history of ulcers) taking conventional NSAIDs or selective COX-2 inhibitors were studied over a 6-mo period; 17.1 and 16.5%, respectively, developed clinically significant ulcers. As well as documenting the high susceptibility of this group of patients to the ulcerogenic effects of NSAIDs, this study confirmed previous reports that selective COX-2 inhibitors offered little, if any, benefit in high- risk patients (Laine, 2006). NSAIDs induce injury/bleeding via three key pathways: inhibition of cyclooxygenase (COX)-1 activity, inhibition of COX-2 activity, and direct cytotoxic effects on the epithelium. Effects produced via only one of these pathways (e.g., selective inhibition of COX-1 or of COX-2) are unlikely to produce significant damage (Wallace, 2008). Gastroduodenal bicarbonate secretion is mediated by prostaglandin E receptors and stimulated by the prostone lubiprostone. Toll-like receptor (TLR)4 signaling is protective against gastric injury. Intestinal alkaline phosphatase (IAP) is a chemosensor that regulates the duodenal mucosal surface ph. ischemia/reperfusion-related gastric mucosal damage. Heat shock protein 70 (HSP70) protects the gastric mucosa through inhibition of apoptosis, proinflammatory cytokines, and cell adhesion molecules (CAMs). HSP90 may be a contributing factor in impaired adaptive cytoprotection. Proteinaseactivated receptor-1 (PAR-1) is protective against Helicobacter-induced gastritis, mediated by the suppression of proinflammatory pathways. IKK β/nf-κb signaling decreases chronic Helicobacterinduced inflammation by inhibiting cellular apoptosis and necrosis. Activation of A2A adenosine receptors decreases inflammation and gastritis but leads to persistent Helicobacter pylori infection (defoneska, 2010). Results and discussions Statistical analyses included the χ² test, logistic regression, and the 95% confidence intervals for the estimated relative risk (odds ratio ) where appropriate. A total of 172 patients were studied. Their demographic characteristics are show in table 1. Lot Demographic characteristic Gender F= 136 (79,1%); M= 36 (20,9%) y= 76 (44,2%) Age y = 76 (44,2%) >85 y = 20 (11,6%) Urban = 122 (70,9%) Mediu Rural = 50 (29,1%) Lipopolysaccharide (LPS) increases gastric permeability; IAP secreted during fat digestion may detoxify colonic LPS. NADPH oxidase activity mediates 204 Table 1. Demographic characteristics The clinical symptoms were uncomplicated (epigastric pain, pirosis, nausea and vomiting, bloating )-93 % or complicated (bleeding)- 7%. (table 2) Lot Clinical symptoms Epigastric pain 100 (58,1%) Pirosis 27 (15,7%) Nausea and vomiting 25 (14,5%) Bloating 8 (4,7%) Upper digestive 12 (7%) hemorrhage Table 2. Clinical symptoms
4 All the patients were considered chronic NSAIDs. 124 patients took group 1 NSAIDs and 38 patients group 2 NSAIDs. In group 1 there were 16 patients taking association of two conventional NSAIDs (table 3). All the patients in group two took only one newer NSAIDs. Group 1 NSAIDs n=124 (72%) Indomethacin: 8 Diclofenac: 42 Ketroprofen: 46 Piroxicam: 12 Diclofenac+Ketoprofen: 6 Indomethacin+Ketoprofen:5 Diclofenac+Piroxicam:5 Table 3.Classification of NSAIDs. Group 2 NSAIDs n=38 (28%) Movalis:10 Etoricoxib: 18 Celecoxib: 20 Because of the practical possibilities the tests for H. Pylori infection were performed only to 120 patients. In this group 68 patients were HP positive (49 of 68 women, 72% and 19 of 68 men, 28%) and 52 patients were HP negative (48 of 52 women,92% and 4 of 52 men, 8%). According with the age, the distribution of patients with H. Pylori infection is presented in table 4. Due to their comorbidities (coronary disease, CHF) many of the patients (128 of 172, 74%) obligatory took aspirin in low prophylactic doses. Low dose-aspirin increases the risk of upper GI bleeding by approximately 2- fold. When NSAIDs are added to low-dose aspirin, the risk of bleeding increases approximately 2- to 4-fold as compared with low-dose aspirin alone (Laine, 2006). 99 patients associated aspirin with group 1 NSAIDs (99 of 124, 80%) and presented the following clinical symptoms: o Epigastric pain: (63 of 99, 63%) o Pirosis ( 13 of 99, 13%) o Nausea and vomiting (10 of 99, 10%) o Bloating (2 of 99, 2%) o Upper digestive hemorrhage (11 of 99, 11%). 29 patients associated aspirin with group 2 NSAIDs (29 of 48, 60%) and presented the following clinical symptoms: o Epigastric pain (18 of 29, 62%) o Pirosis (7 of 29, 24%) o Nausea and vomiting 3 of 29, 10%) o Upper digestive hemorrhage (1 of 29, 3%) Besides personal risk factors, the type and the dose of NSAIDs, duration of exposure to the drug and concomitant use of other drugs play an important role on NSAIDrelated GI side effects. AGE HP PATIENTS Table 4. Correlation of HP infection with age. Epidemiologic studies in elderly people have shown that the prevalence of HP infection increases with age, but tends to decrease after 85 years (Salles,2007 ) The same trend of prevalence curve was also meet in our study. 205 Conclusions Any patient taking NSAIDs has a significantly increased risk of developing GI complications. However, several risk factors lead to a significantly greater increased risk and, when present, should lead to a strong consideration of preventive strategies designed to decrease NSAID GI effects. The 5 risk factors that are most well documented and consistent across studies are: age >65; therapy with oral anticoagulants; corticosteroids and/or aspirin;
5 high-dose/multiple NSAIDs; history of peptic ulcer. Other factors have also been reported to be associated with increases in risk in some studies but not others. These include severity of osteoarthritis, comorbidities such as cardiovascular disease, and psychologic stress. The gastric effects of NSAIDs vary according to their acute or chronic use. Although some epidemiologic studies have suggested that the risk of NSAIDassociated GI events is highest in the first month and decreases markedly with longer use, 30 prospective randomized trials suggest that the rate of GI events remains relatively constant over time, indicating a continued risk and higher cumulative incidence with increasing duration of use (Soylu, 2008). NSAIDs induce clinically significant ulceration, bleeding, and/or obstruction in 1 4% of patients chronically taking these drugs. Even higher rates of ulceration are seen in patients with a history of peptic ulceration; in patients concurrently taking anticoagulants, low-dose aspirin, or glucocorticoids and in the elderly. Concluding all the above all the patients in our study were at high risk, because all of them were aged 65 and over (11.6% over 85 years old) and also were long-term users of NSAIDs. Almost all of the patients had comedication, because of their comorbidities (cardiovascular diseases, osteoporosis, COPD ). In our study the incidence of bleedings was greater, 6.97% (12 of 72) than in other studies (1-4%) and all of them were present in patients taking low-dose aspirin. Due to the many psychotraumatic events elderly patients at high risk to develop psychologic stress and thus, gastritis. Important advances have been made over the past two decades in order to understand the etiopathogenical mechanisms of NSAIDs-induced gastritis. While still not fully understood, the identification of key events in the development of gastritis after NSAID administration has provided many clues as to how to design new anti-inflammatory drugs with greater margins of safety. (phosphatidylcholine-conjugated NSAIDs, terminal prostaglandin synthase inhibitors, gaseous mediatorreleasing NSAIDs) References defoneska A, Kaunitz JD, Gastroduodenal defense. I. Curr Opin Gastroenterol., 26(6):604-10,2010 Laine L, GI risk and risk factors of NSAIDs. J cardiovasc Pharmacol., 47(1):60-66,2006 Salles N.,Mégraud F., Current management of Helicobacter pylori infections in the elderly. Expert Rev, Anti Infect. Ther., 5(5):845-56,2007 Scarpignato C., Nonsteroidal antiinflammatory drugs:how do they damage gastroduodenal mucosa? Dig Dis.13(1):9-39,1995 Soylu A., Dolapcioglu C.,Dolay K.,Ciltas A., Yasar N., Kalayci M., Alis H., Sever N., Endoscopic and histopathological evaluation of acute gastric injury in high-dose acetaminophen and nonsteroidal antiinflammatory drug ingestion with suicidal intent. World J Gastroenterol. 14(43): ,2008 Taha A S, Dahill S., Sturrock R. D., Lee F. D., Russel R. I., Predicting NSAID related ulcers-assessment of clinical an pathological risk factors and importance of differences in NSAID. Gut,35: ,1994 Wallace J.L.,Prostaglandins, NSAIDs, and gastric mucosal protection:why doesn t the stomach digest itself? Physiol.Rev. 88: ,
ulcer healing role 118 Bicarbonate, prostaglandins in duodenal cytoprotection 235, 236
Subject Index Actin cellular forms 48, 49 epidermal growth factor, cytoskeletal change induction in mucosal repair 22, 23 wound repair 64, 65 polyamine effects on cytoskeleton 49 51 S-Adenosylmethionine
More informationHelicobacter and gastritis
1 Helicobacter and gastritis Dr. Hala Al Daghistani Helicobacter pylori is a spiral-shaped gram-negative rod. H. pylori is associated with antral gastritis, duodenal (peptic) ulcer disease, gastric ulcers,
More informationGastrointestinal Safety of Coxibs and Outcomes Studies: What s the Verdict?
Vol. 23 No. 4S April 2002 Journal of Pain and Symptom Management S5 Proceedings from the Symposium The Evolution of Anti-Inflammatory Treatments in Arthritis: Current and Future Perspectives Gastrointestinal
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationPrevalence of gastroduodenal lesions in chronic nonsteroidal anti-inflammatory drug users presenting with dyspepsia at the Kenyatta National Hospital
Research Article Department of Clinical Medicine and Therapeutics, University of Nairobi, Kenya Corresponding author: Dr. G O Oyoo. Email: geomondi@hotmail. com Prevalence of gastroduodenal lesions in
More informationOriginal Article. Abstract. Introduction
Original Article Frequency of NSAID Induced Peptic Ulcer Disease Saeed Hamid, Javed Yakoob, Wasim Jafri, Shanul Islam, Shahab Abid, Muhammad Islam Section of Gastroenterology, Department of Medicine, Aga
More informationNon-steroidal anti-inflammatory drugs and gastrointestinal damage problems and solutions
82 University of Glasgow and Department of Gastroenterology, Royal Infirmary, Glasgow Correspondence to: Professor R I Russell, 28 Ralston Road, Bearsden, Glasgow G61 3BA rirla@aol.com Submitted 26 October
More informationCHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?
CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory
More informationReview Article. Safety Profile of Nonsteroidal Antiflammatory Drugs (NSAID) Safety Profile of NSAID
Safety Profile of Nonsteroidal Antiflammatory Drugs (NSAID) R. Stoilov: University Hospital St Ivan Rilski, Clinic of Rheumatology Contact: Rumen Stoilov, Clinic of Rheumatology, University Hospital St
More informationGastric ulcer Duodenal ulcer Pancreatitis Ileus. Barbora Konečná
Gastric ulcer Duodenal ulcer Pancreatitis Ileus Barbora Konečná basa.konecna@gmail.com Peptic ulcers of stomach and duodenum (PUD) Ulcers are chronic, often solitary lesions, that occur in any part of
More informationHelicobacter pylori:an Emerging Pathogen
Bacteriology at UW-Madison Bacteriology 330 Home Page Helicobacter pylori:an Emerging Pathogen by Karrie Holston, Department of Bacteriology University of Wisconsin-Madison Description of Helicobacter
More informationD DAVID PUBLISHING. 1. Introduction. Maher Mbarki 1, Helen Sklyarova 1, Krystyna Aksentiychuk 1, Ihor Tumak 2 and Eugene Sklyarov 1
Journal of Pharmacy and Pharmacology (2016) 32-36 doi: 10.17265/232-2150/2016.0.011 D DAVID PUBLISHING Plasma Levels of Leukotriene B and Prostaglandin E2 Correlation with Endoscopic Changes after NSAID
More informationORIGINAL ARTICLE. Abstract
ORIGINAL ARTICLE Prescription of Nonsteroidal Anti-inflammatory Drugs and Co-prescribed Drugs for Mucosal Protection: Analysis of the Present Status Based on Questionnaires Obtained from Orthopedists in
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationComparative study of invasive methods for diagnosis of Helicobacter pylori in humans
ISSN: 2319-7706 Volume 2 Number 7 (2013) pp. 63-68 http://www.ijcmas.com Original Research Article Comparative study of invasive methods for diagnosis of Helicobacter pylori in humans V.Subbukesavaraja
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description
More informationThe Association of CagA + Helicobacter pylori Infection and Gastric Carcinoma
The Association of CagA + Helicobacter pylori Infection and Gastric Carcinoma PRESENTER: Dr. Md. Khalilur Rahman Student of M.D.(Internal Medicine) Sylhet MAG Osmani Medical College Gastric Cancer- ranked
More informationDYSPEPSIA IN ACUTE FALCIPARUM MALARIA CLINICO-PATHOLOGICAL CORRELATION
DYSPEPSIA IN ACUTE FALCIPARUM MALARIA CLINICO-PATHOLOGICAL CORRELATION A Pol rat Wilairatana I, Mario Riganti2, Sornchai Looareesuwan I, Benjanee Punpoowong2, Preeya Srisopark2 and Preecha Charoenlarpl
More informationDuodenal histology, ulceration, and Helicobacter pylori in the presence or absence of non-steroidal
1162 Departments of Gastroenterology, A S Taha I Nakshabendi R I Russell Pathology, S Dahill F D Lee and Rheumatology, Royal Infirmary, Glasgow R D Sturrock Correspondence to: Dr A S Taha, Gastroenterology
More informationThe Nobel Prize in Physiology or Medicine for 2005
The Nobel Prize in Physiology or Medicine for 2005 jointly to Barry J. Marshall and J. Robin Warren for their discovery of "the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer
More informationPeptic Ulcer Disease Update
Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following
More informationPeptic ulcer disease. Nomin-Erdene. D SOM-531
Peptic ulcer disease Nomin-Erdene. D SOM-531 Learning objectives Stomach gross anatomy PUD Epidemiology Pathogenesis Clinical manifestation Diagnosing Treatment Complicated ulcer disease Surgical procedures
More informationPain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia
Pain: A Public Health Challenge Despite advances in understanding and treatment, pain remains a major public health challenge 1 that exacts a significant personal and economic toll on Americans. 1 Pain
More informationPain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia
Pain: A Public Health Challenge Despite advances in understanding and treatment, pain remains a major public health challenge 1 that exacts a significant personal and economic toll on Americans 2. Pain
More informationMitigating GI Risks Associated with the Use of NSAIDs
bs_bs_banner Pain Medicine 2013; 14: S18 S22 Wiley Periodicals, Inc. Mitigating GI Risks Associated with the Use of NSAIDs Mahnaz Momeni, MD,* and James D. Katz, MD Departments of *Rheumatology, Medicine,
More informationKK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011
KK College of Nursing Peptic Ulcer Badil Dass, Lecturer 25 th July, 2011 Objectives: By the end of this lecture, the students t will be able to: Define peptic pp ulcer Describe the etiology and pathology
More informationKEYWORDS Dyspepsia, Acid Peptic Disease, Helicobacter Pylori, Urease, Giemsa, Peptic Ulcer, Non-Ulcer Dyspepsia.
INCIDENCE OF HELICOBACTER PYLORI WITH ACID PEPTIC DISEASE AND MALIGNANT CONDITIONS OF UPPER GASTROINTESTINAL TRACT IN A TERTIARY CENTRE - A PROSPECTIVE STUDY Karunamoorthy Rajachidambaram 1, Dinkaran Kaarthesan
More informationGI update. Common conditions and concerns my patients frequently asked about
GI update Common conditions and concerns my patients frequently asked about Specific conditions I ll try to cover today 1. Colon polyps, colorectal cancer and colonoscopy 2. Crohn s disease 3. Peptic ulcer
More informationCyclooxygenase-2 Expression in Gastric Antral Mucosa Before and After Eradication of Helicobacter pylori Infection
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 94, No. 5, 1999 1999 by Am. Coll. of Gastroenterology ISSN 0002-9270/99/$20.00 Published by Elsevier Science Inc. PII S0002-9270(99)00126-4 Cyclooxygenase-2
More informationThe cardioprotective benefits of ... REPORTS... Gastrointestinal Safety of Low-Dose Aspirin. Byron Cryer, MD
... REPORTS... Gastrointestinal Safety of Low-Dose Aspirin Byron Cryer, MD Abstract The cardioprotective benefits of aspirin support the use of low-dose regimens for primary and secondary prevention of
More informationNSAIDs: Side Effects and Guidelines
NSAIDs: Side Effects and James J Hale FY1 Department of Anaesthetics Introduction The non-steroidal anti-inflammatory drugs (NSAIDs) are a diverse group of drugs that have analgesic, antipyretic and anti-inflammatory
More informationSurgery for Complications of Peptic Ulcer Disease (Definitive Treatment)
Surgery for Complications of Peptic Ulcer Disease (Definitive Treatment) Amid Keshavarzi, MD UCHSC Grand Round 3/20/2006 Department of Surgery Introduction Epidemiology Pathophysiology Clinical manifestation
More informationEpidemiology of Peptic Ulcer Disease
Epidemiology of Peptic Ulcer Disease Introduction Peptic Ulcer Disease (PUD) is disruption of the mucosal integrity of the stomach and/or duodenum leading to a local defect or excavation due to active
More informationUrea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013
MP 2.04.04 Urea Breath Test for Diagnosis of Helicobactor pylori Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date 12:2013 Return to Medical Policy Index
More informationHelicobacter pylori Improved Detection of Helicobacter pylori
DOI:http://dx.doi.org/10.7314/APJCP.2016.17.4.2099 RESEARCH ARTICLE Improved Detection of Helicobacter pylori Infection and Premalignant Gastric Mucosa Using Conventional White Light Source Gastroscopy
More informationAssociation of Helicobacter pylori infection with Atrophic gastritis in patients with Dyspepsia
ADVANCES IN BIORESEARCH Adv. Biores., Vol 8 [3] May 2017: 137-141 2017 Society of Education, India Print ISSN 0976-4585; Online ISSN 2277-1573 Journal s URL:http://www.soeagra.com/abr.html CODEN: ABRDC3
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationReview Article. NSAID Gastropathy: An Update on Prevention. Introduction. Risk Factors. Kam-Chuen Lai
Review Article NSAID Gastropathy: An Update on Prevention Kam-Chuen Lai Abstract: Keywords: Adverse reactions to non-steroidal anti-inflammatory drugs (NSAIDs) are common. Upper gastrointestinal complications
More information594 Lewin, Weinstein, and Riddell s Gastrointestinal Pathology and Its Clinical Implications
594 Lewin, Weinstein, and Riddell s Gastrointestinal Pathology and Its Clinical Implications Figure 13-20. Stages in the natural history of H. pylori. Biopsies from the antrum are on the left and the oxyntic
More informationSPECIAL REPORT. Aspirin and Risk of Gastroduodenal Complications
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:725 735 SPECIAL REPORT Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions
More informationNational Digestive Diseases Information Clearinghouse
Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach
More informationBleeds in Cardiovascular Disease
Preventing Gastrointestinal Bleeds in Cardiovascular Disease Patients t on Aspirin i Joel C. Marrs, Pharm.D., BCPS Clinical Assistant Professor OSU/OHSU College of Pharmacy Pharmacy Practice IX (PHAR 766)
More informationUtility of In House made Rapid Urease Broth Test for Detection of Helicobacter pylori Infection in Resource Constraint Settings
Original article: Utility of In House made Rapid Urease Broth Test for Detection of Helicobacter pylori Infection in Resource Constraint Settings 1.Dr. Swati Rahul Dhope, 2. Dr. Sachinkumar Vasantrao Wankhede
More informationNONSTEROIDAL ANTI- INFLAMMATORY DRUGS
NONSTEROIDAL ANTI- INFLAMMATORY DRUGS MRS. M.M. HAS A 3 YR. HX OF PROGRESSIVE RIGHT HIP PAIN. THE PAIN INCREASES WITH WEIGHT BEARING ACTIVITY. PT. HAS BEEN ON ACETAMINOPHEN WITHOUT RELIEF. PERTINENT LABS
More informationTIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain
TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain Second Low-Dose SoluMatrix NSAID from Iroko Now Available by Prescription PHILADELPHIA, June 29, 2015 Iroko Pharmaceuticals, LLC,
More informationGastric Ulcer / Gastritis
Gastric Ulcer / Gastritis Endoscopy Department Patient information leaflet You will only be given this leaflet if you have been diagnosed with gastritis and/or a gastric ulcer. The information below outlines
More informationPhospholipid Association Reduces the Gastric Mucosal Toxicity of Aspirin in Human Subjects
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 94, No. 7, 1999 1999 by Am. Coll. of Gastroenterology ISSN 0002-9270/99/$20.00 Published by Elsevier Science Inc. PII S0002-9270(99)00267-1 Phospholipid Association
More informationHelicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding Patients
Gut and Liver, Vol. 9, No. 3, May 2015, pp. 346-352 ORiginal Article Helicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding
More informationMUSCULOSKELETAL PHARMACOLOGY. A story of the inflamed
MUSCULOSKELETAL PHARMACOLOGY A story of the inflamed 1 INFLAMMATION Pathophysiology Inflammation Reaction to tissue injury Caused by release of chemical mediators Leads to a vascular response Fluid and
More informationDuodenal Ulcer / Duodenitis
Duodenal Ulcer / Duodenitis Endoscopy Department Patient information leaflet You will only be given this leaflet if you have been diagnosed with duodenitis and/or a duodenal ulcer. The information below
More informationProton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs
ORIGINAL ARTICLE Proton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs Yuki Sakamoto, Tadashi Shimoyama, Satoru Nakagawa,
More information中文題目 : 消化性潰瘍合併幽門螺旋桿菌感染無法降低成人氣喘之發生 服務單位 : 台北市立聯合醫院陽明院區一般內科 消化內科 內科部
中文題目 : 消化性潰瘍合併幽門螺旋桿菌感染無法降低成人氣喘之發生 英文題目 :Peptic ulcer disease with Helicobacter pylori infection does not protect against adult asthma 作 1 者 : 張勝雄胡曉雲 2,3 服務單位 : 台北市立聯合醫院陽明院區一般內科 消化內科 內科部 1 國立陽明大學公共衛生學科暨研究所
More informationIn 1971, Sir John Vane proposed that nonsteroidal
Non-steroidal antiinflammatory drugs: facts and fallacies This article serves to review NSAIDs, their mechanism of action and adverse effects, as well as to establish the therapeutic position of the new-generation
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationRole of Helicobacter pylori in ulcer healing and
22 Departments of Gastroenterology G Bianchi Porro F Parente V Imbesi and Rheumatology F Montrone I Caruso L Sacco University Hospital, Milan, Italy Correspondence to: Professor G Bianchi Porro, Gastrointestinal
More informationGastrointestinal Disorders. Disorders of the Esophagus 3/7/2013. Congenital Abnormalities. Achalasia. Not an easy repair. Types
Gastrointestinal Disorders Congenital Abnormalities Disorders of the Esophagus Types Stenosis Atresia Fistula Newborn aspirates while feeding. Pneumonia Not an easy repair Achalasia Lack of relaxation
More informationBGG s FucoMAX TM Fucoidan
BGG s FucoMAX TM Fucoidan Protects Gastrointestinal Tract BGG s FucoMAX TM Fucoidan Protects Gastrointestinal Tract 1 BGG s FucoMAX TM the Proprietary and Potent Source and Formula of Fucoidan, and the
More informationPeptic ulcer disease Disorders of the esophagus
Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth
More informationCorrelation Between Endoscopic and Histological Findings in Different Gastroduodenal Lesion and its Association with Helicobacter Pylori
ORIGINAL ARTICLE Correlation Between Endoscopic and Histological Findings in Different Gastroduodenal Lesion and its Association with Helicobacter Pylori *A. Sultana 1, SM Badruddoza 2, F Rahman 3 1 Dr.
More informationGastrointestinal Markers
Gastrointestinal Markers Session 2 Gastrointestinal System Reference Ranges Optimal Range Ttl Total Protein ti 69 6.9 74 7.4 Globulin 2.4 2.8 BUN 10 16 Creatinine 0.8 1.1 Phosphorous 3.0 4.0 Eosinophils
More informationOSTEOARTHRITIS; EFFICACY AND SAFETY OF ACECLOFENAC IN THE TREATMENT: A RANDOMIZED DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL VERSUS DICLOFENAC
The Professional Medical Journal www.theprofesional.com ORIGINAL PROF-416 OSTEOARTHRITIS; EFFICACY AND SAFETY OF ACECLOFENAC IN THE TREATMENT: A RANDOMIZED DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL VERSUS
More informationAbdominal Pain in a Young Aviator
Abdominal Pain in a Young Aviator Calen N. Wherry, MD, MPH Maj, USAF, MC, FS Peter A. Baldwin, MD, MBA, MPH Capt, USAF, MC, FS USAF School of Aerospace Medicine WPAFB, OH RAM 2013 Distribution A: Approved
More informationThe effect of proton pump inhibitors on the gastric mucosal microenvironment
Original papers The effect of proton pump inhibitors on the gastric mucosal microenvironment Yen-Chun Peng,,, A F, Lan-Ru Huang, A, C, E, Hui-Ching Ho, C, Chi-Sen Chang, C, E, Shou-Wu Lee, E, Ching-Chang
More informationOPEN ACCESS TEXTBOOK OF GENERAL SURGERY
OPEN ACCESS TEXTBOOK OF GENERAL SURGERY PEPTIC ULCER DISEASE PC Bornman RS Du Toit EPIDEMIOLOGY AND PATHOGENESIS The prevalence of duodenal ulcer disease has a variable geographical distribution and differs
More informationGastric atrophy: use of OLGA staging system in practice
Gastroenterology and Hepatology From Bed to Bench. 2016 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE Gastric atrophy: use of OLGA staging system in practice Mahsa
More informationNSAID-Induced Gastrointestinal Damage
GASTROENTEROLOGY BOARD REVIEW MANUAL STATEMENT OF EDITORIAL PURPOSE The Hospital Physician Gastroenterology Board Review Manual is a study guide for fellows and practicing physicians preparing for board
More informationNon-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract
Journal of Gastroenterology and Hepatology (2000) 15, G58 G68 WORKING PARTY REPORT: NSAID Non-steroidal anti-inflammatory drug toxicity in the upper gastrointestinal tract JJY SUNG,* RI RUSSELL, 1 N YEOMANS,
More informationSUMMARY INTRODUCTION. Accepted for publication 22 January 2003
Aliment Pharmacol Ther 23; 17: 1535 1543. doi: 1.146/j.1365-236.23.1587.x Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and
More information6/25/ % 20% 50% 19% Functional Dyspepsia Peptic Ulcer GERD Cancer Other
Peptic Ulcer Disease and Dyspepsia John M. Inadomi, MD Professor of Medicine UCSF Chief, Clinical Gastroenterology San Francisco General Hospital Case History 49 y/o woman complains of several months of
More informationA study on clinical profile and risk factors in drug induced UGI bleeding
Original Research Article A study on clinical profile and risk factors in drug induced UGI bleeding S. Appandraj 1*, V. Sakthivadivel 2 1,2 Associate Professor, Dept. of General Medicine, Karpaga Vinayaga
More informationComplementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib
Aliment Pharmacol Ther 2003; 17: 201 210. doi: 10.1046/j.0269-2813.2003.01407.x Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib R. H. HUNT*,
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationCorrelation between Gastric Mucosal Morphologic Patterns and Histopathological Severity of
Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 808505, 7 pages http://dx.doi.org/10.1155/2015/808505 Research Article Correlation between Gastric Mucosal Morphologic
More informationINVESTIGATIONS OF GASTROINTESTINAL DISEAS
INVESTIGATIONS OF GASTROINTESTINAL DISEAS Lecture 1 and 2 دز اسماعيل داود فرع الطب كلية طب الموصل Radiological tests of structure (imaging) Plain X-ray: May shows soft tissue outlines like liver, spleen,
More informationIbuprofen. Ibuprofen and Paracetamol: prescribing overview. Ibuprofen indications CYCLO-OXYGENASE (COX I) CYCLO-OXEGENASE (COX II) INFLAMMATORY PAIN
Ibuprofen Ibuprofen and Paracetamol: prescribing overview Sarah Holloway Macmillan CNS in palliative care NSAID Non-selective COX inhibitor Oral bioavailability: 90% Onset of action: 20-30 mins (can take
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationNSAIDs Overview. Souraya Domiati, Pharm D, MS
NSAIDs Overview Souraya Domiati, Pharm D, MS Case A 32 years old shows up into your pharmacy asking for an NSAID for his ankle pain He smokes1 pack/day His BP is 125/75mmHg His BMI is 35kg/m2 His is on
More informationMonth/Year of Review: January 2012 Date of Last Review: February 2007
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January 2012 Date of Last Review:
More informationMcHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Optional Continuing Education 2018 #10 Acute GI Bleeds
McHenry Western Lake County EMS System Paramedic, EMT-B and PHRN Optional Continuing Education 2018 #10 Acute GI Bleeds Gastrointestinal bleeding is a very common problem in emergency medicine. Between
More informationNon-steroidal anti-inflammatory drugs: who should receive prophylaxis?
Aliment Pharmacol Ther 2004; 20 (Suppl. 2): 59 64. Non-steroidal anti-inflammatory drugs: who should receive prophylaxis? C. J. HAWKEY Wolfson Digestive Diseases Centre, Institute of Clinical Research,
More informationM Frezza, N Gorji, M Melato. The chronic use of non-steroidal antiinflammatory
J Clin Pathol 2001;54:521 525 521 Unit of Gastroenterology, General Hospital, I-34149 Trieste, Italy M Frezza Department of Pathological Anatomy, General Hospital and University of Trieste N Gorji M Melato
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/48400
More informationUpper Gastrointestinal Manifestations in Chronic Renal Failure Through Upper Gastrointestinal Endoscopy
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2017/249 Upper Gastrointestinal Manifestations in Chronic Renal Failure Through Upper Gastrointestinal Endoscopy Madavaram
More informationHelicobacter pylori: drowning in a pool of blood?
Helicobacter pylori: drowning in a pool of blood? Diagnosis of Helicobacter pylori infection is crucial in the short-term and long-term management of patients with bleeding ulcers. If a patient with ulcer
More informationA bleeding ulcer: What can the GP do? Gastrointestinal bleeding is a relatively common. How is UGI bleeding manifested? Who is at risk?
Focus on CME at the University of British Columbia A bleeding ulcer: What can the GP do? By Robert Enns, MD, FRCP Gastrointestinal bleeding is a relatively common disorder affecting thousands of Canadians
More informationProtection of human gastric mucosa against aspirinðenteric coating or dose reduction?
Aliment Pharmacol Ther 1999; 13: 187±193. Protection of human gastric mucosa against aspirinðenteric coating or dose reduction? A. T. COLE*, N. HUDSON*, L. C. W. LIEW*, F. E. MURRAY*, C. J. HAWKEY* & S.
More informationTRANSPARENCY COMMITTEE OPINION. 13 December 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 December 2006 HELIKIT 75 mg, powder for oral solution CIP : 343 132-1 Applicant : MAYOLY SPINDLER 13 Curea anhydrous
More informationEffective Health Care Program
Comparative Effectiveness Review Number 38 Effective Health Care Program Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review Executive Summary Background Osteoarthritis
More informationCyclooxygenase 2 implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives
Gut 2001;49:443 453 443 Review Cyclooxygenase 2 implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives Summary Cyclooxygenase (COX), the key enzyme
More informationCommensal Bacteria, Toll-like Receptors and Intestinal Injury. Journal Club December 16, 2004
Commensal Bacteria, Toll-like Receptors and Intestinal Injury Journal Club December 16, 2004 Gut-Commensal Interactions Nutrient metabolism Tissue development Resistance to colonization with pathogens
More informationHave COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?
et al. DOI:10.1111/j.1365-2125.2003.02012.x British Journal of Clinical Pharmacology Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Mary Teeling, Kathleen Bennett
More informationCharacteristics of Helicobacter pylorinegative and -positive peptic ulcer disease
Age and Ageing 1998; 27: 427-43 I 1998, British Geriatrics Society Characteristics of Helicobacter pylorinegative and -positive peptic ulcer disease HELENA KEMPPAINEN, ISMO MIHA, HARRY KUJARI 1, LEIF SOURANDER
More informationName: Class: "Pharmacology NSAIDS (1) Lecture
I Name: Class: "Pharmacology NSAIDS (1) Lecture د. احمد الزهيري Inflammation is triggered by the release of chemical mediators from injured tissues and migrating cells. The specific mediators vary with
More informationAli Jaber, Ph.D. MS in Pharmacy MS in Pharmaceutical Chemistry
Nonsteroidal antiinflammatory drugs (NSAID) Ali Jaber, Ph.D. MS in Pharmacy MS in Pharmaceutical Chemistry The inflammatory response occurs in vascularised tissues in response to injury. It is part of
More information5. Which component of the duodenal contents entering the stomach causes the most severe changes to gastric mucosa:
Gastro-intestinal disorders 1. Which are the most common causes of chronic gastritis? 1. Toxic substances 2. Chronic stress 3. Alimentary factors 4. Endogenous noxious stimuli 5. Genetic factors 2. Chronic
More informationDefinition gastritis
Gastritis Definition The term gastritis is used to denote inflammation associated with mucosal injury Gastritis is mostly a histological term that needs biopsy to be confirmed Gastritis is usually due
More informationÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ
ÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ 205 206 ÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ EPITHELIAL CELL TURNOVER IN NON-DYSPLASTIC GASTRIC MUCOSA ADJACENT TO EARLY AND
More informationNonsteroidal anti-inflammatory drugs (NSAIDs),
GASTROENTEROLOGY 2001;120:594 606 Approaches to Nonsteroidal Anti-inflammatory Drug Use in the High-Risk Patient LOREN LAINE University of Southern California School of Medicine, Los Angeles, California
More informationManagement of Dyspepsia
MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively
More informationINTRODUCTION ORIGINAL ARTICLE. Sang Gyun Kim 1, Nayoung Kim 2, Sung Kwan Shin 3, In Kyung Sung 4, Su Jin Hong 5 and Hyo-Jin Park 3
ORIGINAL ARTICLE Clin Endosc 2017;50:179-184 https://doi.org/10.5946/ce.2016.031 Print ISSN 2234-2400 On-line ISSN 2234-2443 Open Access Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant
More information